Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson acquired 8,183 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average price of $22.13 per share, for a total transaction of $181,089.79. Following the completion of the purchase, the chief financial officer directly owned 8,183 shares of the company’s stock, valued at $181,089.79. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Sensei Biotherapeutics Stock Up 2.2%
Sensei Biotherapeutics stock traded up $0.54 during mid-day trading on Wednesday, reaching $24.54. The company’s stock had a trading volume of 102,858 shares, compared to its average volume of 78,057. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on FTH shares. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. HC Wainwright started coverage on Sensei Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 target price for the company. Finally, BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $60.00.
Trending Headlines about Sensei Biotherapeutics
Here are the key news stories impacting Sensei Biotherapeutics this week:
- Positive Sentiment: CEO Anand Kiran Parikh bought 2,806 shares at $19.76 each, signaling confidence in Sensei Biotherapeutics’ outlook. CEO purchase SEC filing
- Positive Sentiment: CFO Brian C. Stephenson bought 9,230 shares at $24.36 each, a larger insider purchase that can be viewed as a strong vote of confidence from management. CFO purchase SEC filing
- Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 price target, while lifting forecasts across multiple future periods, reinforcing a bullish long-term view of the stock. HC Wainwright research note
- Neutral Sentiment: HC Wainwright’s estimates still call for losses over the next several quarters and years, so the outlook remains highly speculative and dependent on future clinical or operational progress.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
